Business
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
Content from the discussion will be featured in upcoming "Diarrhea Dialogues: Part 2"SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc.
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Content from the discussion will be featured in upcoming \"Diarrhea Dialogues: Part 2\"SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting a closed satellite event on December 9, 2021 at SABCS in San Antonio, Texas. The evening includes a discussion with leading oncologists on the debilitating effects of diarrhea experienced as a result of cancer and/or cancer therapy. The event will also include a presentation by Darlene Horton, MD, Napo Pharmaceuticals Chief Medical Officer, on the company's ongoing OnTarget Pivotal Phase 3 trial.OnTarget is the company's pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. The study is enrolling adult patients with solid tumors, including breast cancer patients, requiring targeted therapies with or without cycle chemotherapy. OnTarget is sponsored by Napo Pharmaceuticals, Jaguar Health's wholly owned subsidiary.Content from this session will be recorded and released as the second installment of Jaguar Health's disease education program \"Diarrhea Dialogues.\"PARTICIPANTS:Darlene Horton, MD, Napo Pharmaceuticals Chief Medical OfficerPablo Okhuysen, MD, Professor, Infectious Diseases at University of Texas MD Anderson Cancer CenterLee Schwartzberg, MD, FACP, Professor of Medicine, University of Tennessee Health Science Center; Napo Pharmaceuticals Scientific Advisory Board MemberHALT-D Results Poster PresentationIn addition, data on crofelemer from the investigator-initiated HALT-D trial will be presented by a third-party on Friday, December 10th from 7:00 - 8:30 a.m. CT at SABCS. The HALT-D trial, which is separate from the OnTarget trial, evaluated crofelemer for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane. The virtual poster will be available starting at 7:00 a.m. CT as well.About Cancer Therapy-related DiarrheaA significant proportion of patients undergoing cancer therapy experience diarrhea, and diarrhea has the potential to cause dehydration, potential infections, and non-adherence to treatment in this population. Novel \"targeted cancer therapy\" agents, such as epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs), with ...